Clinical Trials in Austin

Showing 6261-6280 of 15,205 trials

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

NCT04526210

This is a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine the effect of ALXN1840 on the metabolism of bupropion, a sensitive cytochrome P450 2B6 (CYP2B6) substrate, in healthy male and female participants. The safety and tolerability of ALXN1840 will be determined along with ALXN1840 pharmacokinetics (PK) in plasma as measured via total molybdenum with the coadministration of bupropion.

Wilson Disease

Alexion Pharmaceuticals, Inc.54 participantsStarted Oct 2020

Austin, Texas, United States

COMPLETEDPhase 2< 1 mile

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

NCT00350272

Elvucitabine, a novel nucleoside analog, is being studied as a treatment for participants with human immunodeficiency virus (HIV)-1. This Phase 2 study will enroll 60 HIV-1-naive participants to assess the efficacy and safety of elvucitabine compared to lamivudine in combination with tenofovir and efavirenz as measured by changes in the participant's HIV-ribonucleic acid (RNA) level and CD4 cell count. The study treatment will be 12 weeks of blinded study medication followed by an additional 84 weeks of open-label treatment if the participant's response to treatment meets certain endpoints. The pharmacokinetics of elvucitabine will also be assessed during the study.

HIV Infections

Alexion Pharmaceuticals, Inc.76 participantsStarted May 2006

Little Rock, Arkansas, United States • Long Beach, California, United States • Los Angeles, California, United States +23 more locations

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Find Trials by Condition in Austin

DE-117 Spectrum 5 Study

Improving Therapeutic Learning for PTSD

Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Vision Performance Evaluation of TECNIS EYHANCE™ With TECNIS SIMPLICITY™ Compared to TECNIS® 1-piece Intraocular Lenses

Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

Phase 2 Clinical Trial of CartiLife® in the United States

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Resynchronization/Defibrillation for Ambulatory Heart Failure Trial